JP2002522009A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002522009A5 JP2002522009A5 JP2000543584A JP2000543584A JP2002522009A5 JP 2002522009 A5 JP2002522009 A5 JP 2002522009A5 JP 2000543584 A JP2000543584 A JP 2000543584A JP 2000543584 A JP2000543584 A JP 2000543584A JP 2002522009 A5 JP2002522009 A5 JP 2002522009A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- kinase
- acid sequence
- set forth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108091000080 Phosphotransferase Proteins 0.000 description 243
- 102000020233 phosphotransferase Human genes 0.000 description 243
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 208
- 125000003275 alpha amino acid group Chemical group 0.000 description 201
- 150000001413 amino acids Chemical class 0.000 description 171
- 108090000765 processed proteins & peptides Proteins 0.000 description 169
- 229920001184 polypeptide Polymers 0.000 description 168
- 102000004196 processed proteins & peptides Human genes 0.000 description 168
- 230000000694 effects Effects 0.000 description 163
- 201000010099 disease Diseases 0.000 description 109
- 238000000034 method Methods 0.000 description 108
- 108020004707 nucleic acids Proteins 0.000 description 100
- 102000039446 nucleic acids Human genes 0.000 description 100
- 208000035475 disorder Diseases 0.000 description 99
- 150000007523 nucleic acids Chemical class 0.000 description 94
- 239000000523 sample Substances 0.000 description 70
- 239000000126 substance Substances 0.000 description 67
- 239000002773 nucleotide Substances 0.000 description 62
- 125000003729 nucleotide group Chemical group 0.000 description 62
- 241000124008 Mammalia Species 0.000 description 59
- 210000004027 cell Anatomy 0.000 description 41
- 239000012634 fragment Substances 0.000 description 35
- 208000024172 Cardiovascular disease Diseases 0.000 description 30
- 206010028980 Neoplasm Diseases 0.000 description 30
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 30
- 208000001647 Renal Insufficiency Diseases 0.000 description 30
- 208000006011 Stroke Diseases 0.000 description 30
- 201000011510 cancer Diseases 0.000 description 30
- 201000006370 kidney failure Diseases 0.000 description 30
- 208000010125 myocardial infarction Diseases 0.000 description 30
- 208000015122 neurodegenerative disease Diseases 0.000 description 30
- 239000002853 nucleic acid probe Substances 0.000 description 30
- 210000000056 organ Anatomy 0.000 description 30
- 230000036542 oxidative stress Effects 0.000 description 30
- 238000002054 transplantation Methods 0.000 description 30
- 230000000295 complement effect Effects 0.000 description 26
- 208000037765 diseases and disorders Diseases 0.000 description 26
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 20
- 101000573441 Homo sapiens Misshapen-like kinase 1 Proteins 0.000 description 16
- 230000009870 specific binding Effects 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 101000987297 Homo sapiens Serine/threonine-protein kinase PAK 4 Proteins 0.000 description 15
- 101000987295 Homo sapiens Serine/threonine-protein kinase PAK 5 Proteins 0.000 description 15
- 101000983111 Homo sapiens Serine/threonine-protein kinase PAK 6 Proteins 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 15
- 230000027455 binding Effects 0.000 description 14
- 241000972773 Aulopiformes Species 0.000 description 10
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 10
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 10
- 238000009396 hybridization Methods 0.000 description 10
- 210000004408 hybridoma Anatomy 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 230000003993 interaction Effects 0.000 description 10
- 229940043355 kinase inhibitor Drugs 0.000 description 10
- 238000012544 monitoring process Methods 0.000 description 10
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 10
- 235000019515 salmon Nutrition 0.000 description 10
- 238000013518 transcription Methods 0.000 description 10
- 230000035897 transcription Effects 0.000 description 10
- 238000005406 washing Methods 0.000 description 9
- -1 25A nucleic acid Chemical class 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 102100026287 Misshapen-like kinase 1 Human genes 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- 102100027940 Serine/threonine-protein kinase PAK 4 Human genes 0.000 description 3
- 102100026840 Serine/threonine-protein kinase PAK 6 Human genes 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- 108010076039 Polyproteins Proteins 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8178498P | 1998-04-14 | 1998-04-14 | |
| US60/081,784 | 1998-04-14 | ||
| PCT/US1999/008150 WO1999053036A2 (en) | 1998-04-14 | 1999-04-13 | Ste20-related protein kinases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002522009A JP2002522009A (ja) | 2002-07-23 |
| JP2002522009A5 true JP2002522009A5 (enExample) | 2006-05-25 |
Family
ID=22166386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000543584A Withdrawn JP2002522009A (ja) | 1998-04-14 | 1999-04-13 | Ｓｔｅ−２０関連蛋白質キナーゼ |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US6680170B2 (enExample) |
| EP (1) | EP1073723B1 (enExample) |
| JP (1) | JP2002522009A (enExample) |
| AT (1) | ATE302269T1 (enExample) |
| AU (1) | AU3642499A (enExample) |
| CA (1) | CA2369172A1 (enExample) |
| DE (1) | DE69926742T2 (enExample) |
| DK (1) | DK1073723T3 (enExample) |
| ES (1) | ES2248997T3 (enExample) |
| WO (1) | WO1999053036A2 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7078182B1 (en) * | 1998-04-14 | 2006-07-18 | Board Of Regents, The University Of Texas System | TAO protein kinase polypeptides and methods of use therefor |
| US6013500A (en) | 1998-05-21 | 2000-01-11 | The Trustees Of Columbia University In The City Of New York | PAK4, a novel gene encoding a serine/threonine kinase |
| EP1112368A1 (en) * | 1998-09-10 | 2001-07-04 | Smithkline Beecham Plc | Use of protein kinase kiaa0551 as pharmaceutical |
| CA2362936A1 (en) * | 1999-02-19 | 2000-08-24 | Mcmaster University | A caspase activated protein kinase |
| AU3566200A (en) * | 1999-04-01 | 2000-10-23 | Astrazeneca Uk Limited | Human signal transduction serine/threonine protein kinase |
| US6558903B1 (en) * | 1999-06-30 | 2003-05-06 | Millennium Pharmaceuticals, Inc. | Kinases and uses thereof |
| AU6181000A (en) * | 1999-07-29 | 2001-02-19 | Chugai Research Institute For Molecular Medicine, Inc. | Novel genes encoding protein kinase/protein phosphatase |
| US20030104622A1 (en) * | 1999-09-01 | 2003-06-05 | Robbins Paul D. | Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses |
| US6861239B1 (en) | 1999-09-20 | 2005-03-01 | New York University | Genes and polynucleotides associated with ultraviolet radiation-mediated skin damage and uses thereof |
| WO2001036602A2 (en) * | 1999-11-15 | 2001-05-25 | Pharmacia Italia S.P.A. | Pak5 a member of the p21-activated kinase (pak) protein family, nucleic acids and methods related to the same |
| EP1254214A2 (en) * | 2000-01-25 | 2002-11-06 | Sugen, Inc. | Human protein kinases and protein kinase-like enzymes |
| EP1385992A2 (en) * | 2000-09-20 | 2004-02-04 | Kinetek Pharmaceuticals, Inc. | Cancer associated protein kinases and their uses |
| AU2002243539A1 (en) * | 2001-01-12 | 2002-07-24 | Incyte Genomics, Inc. | Molecules for disease detection and treatment |
| US7265214B2 (en) * | 2001-10-19 | 2007-09-04 | Rigel Pharmaceuticals, Inc. | Germinal center kinase proteins, compositions and methods of use |
| JP2005518198A (ja) | 2001-12-28 | 2005-06-23 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | Ｐａｋ５関連の組成物及び方法 |
| US7439329B2 (en) * | 2002-07-05 | 2008-10-21 | Sugen, Inc. | GEF-H1b: biomarkers, complexes assays and therapeutic uses thereof |
| GB0220770D0 (en) * | 2002-09-06 | 2002-10-16 | Ares Trading Sa | Proteins |
| US20050054017A1 (en) * | 2002-11-27 | 2005-03-10 | Sugen, Inc. | Phosphospecific PAK antibodies and diagnostic kits |
| AU2003296696A1 (en) * | 2002-12-23 | 2004-07-14 | Devgen Nv | Kinase sequences |
| GB2396615A (en) * | 2002-12-23 | 2004-06-30 | Devgen Nv | Kinase sequences useful for developing compounds for the prevention and/or treatment of metabolic diseases |
| US20040242461A1 (en) * | 2003-04-08 | 2004-12-02 | Schneider Michael D. | Modulators of telomere stability |
| DK1653844T3 (da) * | 2003-08-13 | 2013-03-11 | Novartis Vaccines & Diagnostic | Prionspecifikke peptidreagenser |
| US20060035242A1 (en) * | 2004-08-13 | 2006-02-16 | Michelitsch Melissa D | Prion-specific peptide reagents |
| AU2004275876B2 (en) * | 2003-09-25 | 2011-03-31 | Coley Pharmaceutical Gmbh | Nucleic acid-lipophilic conjugates |
| WO2005111234A2 (en) * | 2004-05-12 | 2005-11-24 | Sugen, Inc. | Methods of using zc1 and zc3 kinase substrate phosphorylation as biomarkers |
| NZ587255A (en) * | 2005-01-13 | 2012-03-30 | Novartis Vaccines & Diagnostic | Elisa assays using prion-specific peptide reagents |
| WO2006076683A2 (en) * | 2005-01-13 | 2006-07-20 | Novartis Vaccines And Diagnostics Inc. | Isolation and detection of pathogenic prions |
| US20090099343A1 (en) * | 2005-01-13 | 2009-04-16 | David Peretz | Isolation of pathogenic prions |
| NZ566020A (en) * | 2005-09-09 | 2012-08-31 | Novartis Ag | Prion-specific peptoid reagents |
| WO2009134942A1 (en) * | 2008-04-30 | 2009-11-05 | Novartis Ag. | Assay for pathogenic conformers |
| KR101219395B1 (ko) * | 2010-07-15 | 2013-01-11 | 전자부품연구원 | 리튬이차전지용 양극재료 및 그의 제조방법 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4343940A (en) | 1979-02-13 | 1982-08-10 | Mead Johnson & Company | Anti-tumor quinazoline compounds |
| DE3069468D1 (en) | 1979-12-19 | 1984-11-22 | Nat Res Dev | Quinazoline derivatives, processes for their preparation, compositions containing them and their use as anti-cancer agents |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| DE3611194A1 (de) | 1986-04-04 | 1987-10-08 | Bayer Ag | Cancerostatisches mittel |
| US5217999A (en) | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
| DE3920029C2 (de) | 1988-06-30 | 1999-05-20 | Clariant Finance Bvi Ltd | Farbstoffe zum Färben von Kunststoffen |
| ATE114661T1 (de) | 1990-04-02 | 1994-12-15 | Pfizer | Benzylphosphonsäure-tyrosinkinaseinhibitoren. |
| US5302606A (en) | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
| AU658646B2 (en) | 1991-05-10 | 1995-04-27 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| JPH06503095A (ja) | 1991-05-29 | 1994-04-07 | ファイザー・インコーポレーテッド | 三環式ポリヒドロキシ系のチロシンキナーゼ阻害薬 |
| NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| US5298422A (en) | 1991-11-06 | 1994-03-29 | Baylor College Of Medicine | Myogenic vector systems |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| GB9205320D0 (en) | 1992-03-11 | 1992-04-22 | Ici Plc | Anti-tumour compounds |
| EP0654024A1 (en) | 1992-08-06 | 1995-05-24 | Warner-Lambert Company | 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties |
| US5330992A (en) | 1992-10-23 | 1994-07-19 | Sterling Winthrop Inc. | 1-cyclopropyl-4-pyridyl-quinolinones |
| US5366889A (en) * | 1992-11-30 | 1994-11-22 | The General Hospital Corporation | DNA encoding a protein-coupled receptor kinase |
| GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
| GB9501567D0 (en) | 1995-01-26 | 1995-03-15 | Pharmacia Spa | Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors |
| US5830699A (en) * | 1996-05-07 | 1998-11-03 | The General Hospital Corporation | SOK-1 and methods of use |
| AU4448597A (en) | 1996-10-04 | 1998-05-05 | Connaught Laboratories Limited | Treatment of cancer using a recombinant poxvirus containing nucleic acid sequence encoding a cytokine |
| AU8296698A (en) * | 1997-07-08 | 1999-02-08 | Cadus Pharmaceutical Corporation | (kds) protein kinase molecules and uses related thereto |
| AU8778698A (en) * | 1997-08-11 | 1999-03-01 | Ontogeny, Inc. | Serine/threonine kinase, and uses related thereto |
| GB9719920D0 (en) * | 1997-09-19 | 1997-11-19 | Zeneca Ltd | Human Ste20-Like Stress Activated Serine/Threonine Kinase |
| GB9726851D0 (en) * | 1997-12-19 | 1998-02-18 | Zeneca Ltd | Human signal transduction serine/threonine kinase |
| US6013500A (en) * | 1998-05-21 | 2000-01-11 | The Trustees Of Columbia University In The City Of New York | PAK4, a novel gene encoding a serine/threonine kinase |
-
1999
- 1999-04-13 DE DE69926742T patent/DE69926742T2/de not_active Expired - Fee Related
- 1999-04-13 WO PCT/US1999/008150 patent/WO1999053036A2/en not_active Ceased
- 1999-04-13 DK DK99918539T patent/DK1073723T3/da active
- 1999-04-13 US US09/291,417 patent/US6680170B2/en not_active Expired - Fee Related
- 1999-04-13 JP JP2000543584A patent/JP2002522009A/ja not_active Withdrawn
- 1999-04-13 AU AU36424/99A patent/AU3642499A/en not_active Abandoned
- 1999-04-13 ES ES99918539T patent/ES2248997T3/es not_active Expired - Lifetime
- 1999-04-13 AT AT99918539T patent/ATE302269T1/de not_active IP Right Cessation
- 1999-04-13 CA CA002369172A patent/CA2369172A1/en not_active Abandoned
- 1999-04-13 EP EP99918539A patent/EP1073723B1/en not_active Expired - Lifetime
-
2000
- 2000-10-16 US US09/688,188 patent/US6656716B1/en not_active Expired - Fee Related
-
2003
- 2003-12-02 US US10/725,329 patent/US20040224323A1/en not_active Abandoned
- 2003-12-02 US US10/725,121 patent/US20050142625A1/en not_active Abandoned
- 2003-12-02 US US10/725,330 patent/US20070072261A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002522009A5 (enExample) | ||
| JP2003501038A5 (enExample) | ||
| EP1730181A2 (en) | Novel brain natriuretic peptide variants and methods of use thereof | |
| JP2003519463A (ja) | ＴＣＬ−１ｂ遺伝子、蛋白質、それらに関連した方法およびそれらに関連する物質 | |
| EP2572721B1 (en) | Pharmaceutical composition including an hif-2 inhibitor as an active ingredient for preventing or treating arthritis | |
| JP3681384B2 (ja) | Ｇｄｐ交換因子活性を有するペプチド，それらのペプチドをコードする核酸配列，調製法，およびに，使用 | |
| US6197505B1 (en) | Methods for assessing cardiovascular status and compositions for use thereof | |
| US7148002B2 (en) | Nucleic acids and polypeptides related to a guanine exchange factor of Rho GTPase | |
| RU2004117536A (ru) | Новые изоформы ингибитора роста васкулярных эндотелиальных клеток | |
| JP2002508923A5 (enExample) | ||
| JPH09509319A (ja) | Ｒｎａ修正酵素およびその使用方法 | |
| JP4629873B2 (ja) | 単球由来核酸および関連する組成物ならびに方法 | |
| JP2002518016A5 (enExample) | ||
| KR20060116825A (ko) | 바이러스 감염에 대한 저항성과 관련된 유전자인ｏａｓ1에서의 돌연변이의 검출 | |
| JPH06503475A (ja) | 生来のタイプ２ｇａｐ、種々のｇａｐの精製方法及び癌診断へのｇａｐの使用 | |
| KR20190111845A (ko) | 줄기세포의 노화 예측 또는 진단용 바이오 마커 | |
| CA2408847A1 (en) | Cng3b: a novel cyclic nucleotide-gated cation channel | |
| JP2017135985A (ja) | Ｂ前駆細胞性急性リンパ芽球性白血病新規キメラ遺伝子 | |
| CN108329387A (zh) | 癌症相关的肿瘤特异转录本lin28b-tst及其用途 | |
| LORENZI et al. | Two mRNAs are transcribed from the human gene for choline acetyltransferase | |
| CA2370519A1 (en) | Nucleic acids encoding a mutt domain-containing polypeptide | |
| US20040072186A1 (en) | Transglutaminase gene products | |
| JP2005508157A5 (enExample) | ||
| CA3148273A1 (en) | Compositions and methods utilizing a novel human foxo3 isoform | |
| WO2003002146A1 (fr) | Composition medicinale |